Elevance Health (NYSE:ELV) Coverage Initiated by Analysts at Evercore

Equities researchers at Evercore assumed coverage on shares of Elevance Health (NYSE:ELV) in a research report issued to clients and investors on Wednesday, MarketBeat reports. The brokerage set an “in-line” rating and a $345.00 price target on the stock. Evercore’s target price points to a potential upside of 8.63% from the stock’s current price.

Several other research analysts have also recently issued reports on ELV. Morgan Stanley cut their price objective on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. Guggenheim cut their price objective on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Mizuho cut their price objective on Elevance Health from $413.00 to $350.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. UBS Group set a $400.00 price objective on Elevance Health in a research report on Thursday, January 29th. Finally, Barclays cut their price objective on Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Twelve equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Elevance Health currently has a consensus rating of “Hold” and a consensus price target of $385.38.

Elevance Health Stock Performance

ELV traded up $5.77 during trading on Wednesday, hitting $317.60. The stock had a trading volume of 68,717 shares, compared to its average volume of 1,888,620. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The firm has a market capitalization of $69.77 billion, a P/E ratio of 12.59, a PEG ratio of 1.65 and a beta of 0.49. The company’s 50-day moving average price is $312.98 and its 200 day moving average price is $332.28. Elevance Health has a twelve month low of $273.71 and a twelve month high of $444.37.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the company posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities research analysts forecast that Elevance Health will post 33.96 EPS for the current fiscal year.

Institutional Trading of Elevance Health

Large investors have recently bought and sold shares of the company. Murphy Middleton Hinkle & Parker Inc. acquired a new stake in shares of Elevance Health during the fourth quarter valued at $5,941,000. Evergreen Wealth Management LLC boosted its stake in shares of Elevance Health by 33.5% during the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock valued at $5,584,000 after acquiring an additional 4,336 shares during the last quarter. Blume Capital Management Inc. boosted its stake in shares of Elevance Health by 236.7% during the third quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock valued at $1,986,000 after acquiring an additional 4,320 shares during the last quarter. Canoe Financial LP boosted its stake in shares of Elevance Health by 18.1% during the third quarter. Canoe Financial LP now owns 389,399 shares of the company’s stock valued at $125,823,000 after acquiring an additional 59,743 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Elevance Health by 31.1% during the third quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock valued at $149,182,000 after acquiring an additional 109,462 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: CMS finalized a 2.48% Medicare Advantage payment rate increase for 2027, and officials signaled an additional ~2.5% boost from risk‑adjustment changes — pushing the effective increase nearer to ~5%, which materially improves government program revenue outlook for ELV. Elevance Health Stock Soars After 2.48% Medicare Rate Increase
• Positive Sentiment: Bank of America updated its managed‑care outlook and raised its price target on Elevance, signaling analyst confidence that the CMS decision and structural dynamics support higher fair value. BofA Updates Managed Care Outlook, Raises Elevance Health (ELV) Price Target
• Positive Sentiment: Several analysts and outlets call the new rate a near‑term catalyst; some technical and valuation takes argue ELV is attractively priced after recent underperformance, supporting a buy case if fundamentals stabilize. Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good
• Neutral Sentiment: Earnings previews and analyst notes remind investors that Elevance still faces membership declines, higher benefit expense ratios and muted guidance — the CMS boost helps, but underlying operational trends will determine sustainability. Elevance Health earnings preview: What to expect
• Neutral Sentiment: Analysis pieces digging into the CMS change offer modeling details on how the rate and risk‑adjustment shifts flow to margins and EPS — useful for investors but dependent on enrollment and expense trends. Medicare Rates Up – What This Really Means For Elevance
• Negative Sentiment: Some analysts are cautious: Evercore ISI reinstated ELV at inline and asked whether the Medicare bounce is already priced in, implying upside may be limited if expectations are aggressive. Elevance Health Reinstated at Inline by Evercore ISI
• Negative Sentiment: Outlets urging a reassessment note ELV has slid ~27% over the last year and that valuation and operational headwinds (membership pressure, benefit costs) may still warrant caution despite the CMS news. Is It Time To Reassess Elevance Health (ELV) After A 27% One-Year Share Price Slide

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.